NCI Funding for HIV and AIDS Malignancies Research

Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer 

This funding opportunity announcement solicits projects that focus on the biological interactions of cancer health disparities in PLWH from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

Additional Information:
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas in HIV/AIDS research related to coinfections, comorbidities, and complications.

Additional Information:
Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1-Clinical Trial Optional)

The role of Epstein Barr Virus (EBV) infection in Non- Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection

This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).

Additional Information:
The role of Epstein Barr Virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries

The goals of this FOA is to solicit R01 applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and the quality of life of People Living with HIV/AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of stigmas at individual levels. For example support intervention research on strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections.

Additional Information:
Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R01 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions

The goals of this program are to support locally relevant research in critical areas of HIV- associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers both within and across LMICs to address this critical burden. NCI is interested in research projects aimed at identifying specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of cancer, or provide information on the clinical outcomes in people living with HIV and cancer.

Additional Information:
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

Notice of Special Interest (NOSI): Use of Biological "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers

The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. Research efforts that identify specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of these cancers and provide information on the clinical outcomes of such cancers in the HIV-infected population are sought. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

High or medium priority AIDS research as described in NOT-OD-15-137 is encouraged in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

Multidisciplinary Studies of HIV/AIDS and Aging

This initiative solicits applications at the intersection of HIV and aging.  NCI is interested in studies that help to understand how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer.

Additional Information:
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)